Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.272 USD | -1.98% | -9.63% | +61.90% |
May. 14 | Transcript : BioLargo, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | BioLargo, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+61.90% | 82.37M | - | ||
+4.86% | 104B | A- | ||
-10.06% | 60.79B | A- | ||
+64.76% | 51.13B | B | ||
+14.74% | 38.21B | B | ||
-0.02% | 30.75B | A- | ||
+11.82% | 19.83B | B- | ||
+10.49% | 16.5B | C+ | ||
+7.90% | 13.82B | B- | ||
-4.54% | 13.33B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- BLGO Stock
- Ratings BioLargo, Inc.